Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06864026 · ClinicalTrials.gov registry record · Phase 4
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
A Phase 4 study of Psoriatic Arthritis and Overweight or Obesity, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT06864026 is a Phase 4 study of Psoriatic Arthritis and Overweight or Obesity that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 200 participants, below the 849-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 2 states.
The verdict
NCT06864026, a Phase 4 study of Psoriatic Arthritis and Overweight or Obesity, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
Conditions Studied
Interventions
- DRUG Tirzepatide
Study Locations (20)
Arizona
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale - Avondale
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Chandler - Chandler
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Flagstaff - Flagstaff
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Gilbert - Gilbert
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Glendale - Glendale
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Mesa - Mesa
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Phoenix PV - Phoenix
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Sun City - Sun City
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Tucson - Tucson
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Tucson Southeast - Tucson
California
- Medvin Clinical Research - Apple Valley - Apple Valley
- Medvin Clinical Research - Covina - Covina
- Newport Huntington Medical Group - Huntington Beach
- Purushotham & Akther Kotha MD, Inc - La Mesa
- Medvin Clinical Research - Riverside - Riverside
- Rheumatology Center of San Diego - San Diego
- Providence Saint John's Medical Foundation - Santa Monica
- Medvin Clinical Research - Temecula - Temecula
- Medvin Clinical Research - Tujunga - Tujunga
- Medvin Clinical Research - Whittier - Whittier
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-03-06 |
| Est. Completion | 2027-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06864026
The ClinicalTrials.gov registry entry for NCT06864026 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 849-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (76% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Psoriatic Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Tirzepatide is the first listed.
NCT06864026 reports 20 study locations spanning 2 distinct geographic areas - top geographies include Arizona, California.
Frequently Asked Questions
What is clinical trial NCT06864026 about?
NCT06864026 is a clinical study titled "A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)". The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
What is the current status of trial NCT06864026?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2025-03-06. Estimated completion is 2027-11.
What conditions does trial NCT06864026 study?
This clinical trial studies the following conditions: Psoriatic Arthritis, Overweight or Obesity.
What interventions are being tested in trial NCT06864026?
The interventions under investigation include: Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT06864026?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06864026 being conducted?
This trial has 20 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
RECRUITING · Phase 4
-
Centocor Microarray Study of Patients
COMPLETED · Phase 4
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Rheumatology Diet Study
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Stronger Together Psoriatic Arthritis Wellness Study
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.